ANRO vs BIO · $60.1M cap vs rev $651.0M
Alto Neuroscience, Inc. (ANRO) versus BIO (BIO) — a side-by-side from cached financials, not a winner call.
Alto Neuroscience, Inc. (ANRO) is a biotechnology company listed on US.
BIO (BIO) common stock.
ANRO does not have a complete income-statement cache yet.
Latest reported BIO revenue for 2026-06-30 was $651.0M. Net income was $371.4M. Revenue was up 9.9% from 2026-03-31 to 2026-06-30. BIO currently screens at market cap $0.
ANRO currently screens at market cap $60.1M. BIO currently screens at market cap $0.
Not investment advice. Open the ANRO and BIO stock pages for the full models.
Not investment advice.